AU2013266438B2 - Pyrimidine compounds for the treatment of cancer - Google Patents

Pyrimidine compounds for the treatment of cancer Download PDF

Info

Publication number
AU2013266438B2
AU2013266438B2 AU2013266438A AU2013266438A AU2013266438B2 AU 2013266438 B2 AU2013266438 B2 AU 2013266438B2 AU 2013266438 A AU2013266438 A AU 2013266438A AU 2013266438 A AU2013266438 A AU 2013266438A AU 2013266438 B2 AU2013266438 B2 AU 2013266438B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
alkyl
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2013266438A
Other languages
English (en)
Other versions
AU2013266438A1 (en
Inventor
Dmitri Kireev
Andrew MCIVER
Xiaodong Wang
Dehui Zhang
Weihe Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of AU2013266438A1 publication Critical patent/AU2013266438A1/en
Application granted granted Critical
Publication of AU2013266438B2 publication Critical patent/AU2013266438B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013266438A 2012-05-22 2013-05-21 Pyrimidine compounds for the treatment of cancer Expired - Fee Related AU2013266438B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650000P 2012-05-22 2012-05-22
US61/650,000 2012-05-22
PCT/US2013/042033 WO2013177168A1 (en) 2012-05-22 2013-05-21 Pyrimidine compounds for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2013266438A1 AU2013266438A1 (en) 2014-12-04
AU2013266438B2 true AU2013266438B2 (en) 2017-09-07

Family

ID=49624289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013266438A Expired - Fee Related AU2013266438B2 (en) 2012-05-22 2013-05-21 Pyrimidine compounds for the treatment of cancer

Country Status (14)

Country Link
US (1) US9567326B2 (enExample)
EP (1) EP2852579A4 (enExample)
JP (1) JP2015517574A (enExample)
KR (1) KR20150018789A (enExample)
CN (1) CN104302627A (enExample)
AU (1) AU2013266438B2 (enExample)
BR (1) BR112014028424A2 (enExample)
CA (1) CA2873878A1 (enExample)
HK (1) HK1206338A1 (enExample)
IL (1) IL235726A0 (enExample)
IN (1) IN2014DN09610A (enExample)
MX (1) MX2014013632A (enExample)
RU (1) RU2014145121A (enExample)
WO (1) WO2013177168A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
CA2850617A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
BR112014028424A2 (pt) 2012-05-22 2018-04-24 Univ North Carolina Chapel Hill compostos de pirimidina para o tratamento de câncer
EP2903617B1 (en) * 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
WO2015157122A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
US10710983B2 (en) * 2016-06-27 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
CN106749173A (zh) * 2016-11-25 2017-05-31 吉林化工学院 一种嘧啶联吡啶类化合物的制备方法
CN117736188A (zh) 2017-05-02 2024-03-22 韩国化学研究院 包含嘧啶衍生物化合物为有效成分的Tyro3相关疾病的预防或治疗用组合物
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
KR102616469B1 (ko) * 2020-09-15 2023-12-28 주식회사 유엔에스바이오 혈액 순환 미세체외소체 매개 암 치료용 조성물
WO2022059996A1 (ko) * 2020-09-15 2022-03-24 서울대학교 기술지주 주식회사 혈액 순환 미세체외소체 매개 암 치료용 조성물
KR20230144529A (ko) * 2020-12-16 2023-10-16 에이비엠 쎄라퓨틱스 코포레이션 키나아제 억제제 및 이의 용도
CN119059982B (zh) * 2024-07-18 2025-09-19 河北科技大学 一种异羟肟酸类Mer/HDAC双靶点抑制剂及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009443A1 (en) * 2003-06-24 2005-02-03 Amgen Inc. 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2007041379A1 (en) * 2005-09-30 2007-04-12 Bristol-Myers Squibb Company Met kinase inhibitors
EP2133095A1 (en) * 2007-03-05 2009-12-16 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
WO2011090760A1 (en) * 2009-12-29 2011-07-28 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2013157540A1 (ja) * 2012-04-17 2013-10-24 富士フイルム株式会社 含窒素複素環化合物またはその塩

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) * 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
US20080248046A1 (en) 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU4114201A (en) * 2000-04-28 2001-11-12 Tanabe Seiyaku Co Cyclic compounds
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003029209A2 (en) 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
MXPA04012855A (es) * 2002-06-28 2005-04-19 Yamanouchi Pharma Co Ltd Derivado de diaminopirimidincarboxiamida.
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7589086B2 (en) 2003-05-28 2009-09-15 Universita Degli Studi Di Siena Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
DE602005023587D1 (de) 2004-01-21 2010-10-28 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1749827A4 (en) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd ANTITUMOR AGENTS
EP1732541A4 (en) 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
RU2405778C2 (ru) * 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
US20070105874A1 (en) 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
CN101321751A (zh) * 2005-09-30 2008-12-10 布里斯托尔-迈尔斯·斯奎布公司 Met激酶抑制剂
EP1940847A2 (en) 2005-10-06 2008-07-09 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
KR101373464B1 (ko) 2005-12-08 2014-03-14 메다렉스, 엘.엘.시. 단백질 티로신 키나제 7(ｐｔｋ7)에 대한 인간 단일클론항체 및 그의 용도
EP1979002A2 (en) 2005-12-19 2008-10-15 OSI Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
RU2480464C2 (ru) 2006-03-30 2013-04-27 Тиботек Фармасьютикалз Лтд. 5-амидо-замещенные пиримидины, ингибирующие вич
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
JP5681855B2 (ja) 2007-10-12 2015-03-11 アストラゼネカ エービー プロテインキナーゼの阻害剤
JP2011514881A (ja) 2007-11-09 2011-05-12 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ 免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
TWI546290B (zh) * 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
AR073760A1 (es) * 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
GB0819105D0 (en) 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
JP2013504543A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 二環ヘテロアリール類のエーテル誘導体
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
CA2850617A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
WO2013124324A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
BR112014028424A2 (pt) 2012-05-22 2018-04-24 Univ North Carolina Chapel Hill compostos de pirimidina para o tratamento de câncer
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US20170202847A1 (en) 2014-04-04 2017-07-20 The University Of North Carolina At Chapel Hill Methods for the treatment of tumors
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009443A1 (en) * 2003-06-24 2005-02-03 Amgen Inc. 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2007041379A1 (en) * 2005-09-30 2007-04-12 Bristol-Myers Squibb Company Met kinase inhibitors
EP2133095A1 (en) * 2007-03-05 2009-12-16 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
WO2011090760A1 (en) * 2009-12-29 2011-07-28 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2013157540A1 (ja) * 2012-04-17 2013-10-24 富士フイルム株式会社 含窒素複素環化合物またはその塩

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ishida, H., et al. "Novel and orally active 5-(1, 3, 4-oxadiazol-2-yl) pyrimidine derivatives as selective FLT3 inhibitors." Bioorganic & medicinal chemistry letters, vol 18 (2008): 5472-5477. *
Ismail, M.A. "Efficient synthesis of 5-(5-aryl-2-furyl)pyrimidine derivatives" Mansoura Science Bulletin, A: Chemistry, 30(2) 2003, pp. 157-172 & CAS Registry Number 837415-89-1 *
Pawar M.J. et al "Synthesis of 2,4,5-trisubstituted pyrimidines" Indian Journal of Heterocyclic Chemistry, National Academy of Chemistry and Biology, 20 (2010), page 133-136 *

Also Published As

Publication number Publication date
US20150038481A1 (en) 2015-02-05
CN104302627A (zh) 2015-01-21
AU2013266438A1 (en) 2014-12-04
EP2852579A1 (en) 2015-04-01
HK1206338A1 (en) 2016-01-08
IL235726A0 (en) 2015-02-01
BR112014028424A2 (pt) 2018-04-24
US9567326B2 (en) 2017-02-14
CA2873878A1 (en) 2013-11-28
WO2013177168A1 (en) 2013-11-28
KR20150018789A (ko) 2015-02-24
EP2852579A4 (en) 2015-12-30
JP2015517574A (ja) 2015-06-22
RU2014145121A (ru) 2016-07-10
IN2014DN09610A (enExample) 2015-07-31
MX2014013632A (es) 2015-02-05

Similar Documents

Publication Publication Date Title
AU2013266438B2 (en) Pyrimidine compounds for the treatment of cancer
AU2012318896B2 (en) Pyrrolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) Pyrimidine compounds for the treatment of cancer
US9562047B2 (en) Pyrazolopyrimidine compounds for the treatment of cancer
US9744172B2 (en) Pyrazolopyrimidine compounds for the treatment of cancer
CN107108527A (zh) 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂
US20080319044A1 (en) Compounds and Methods of Use Thereof
HK1201256B (en) Pyrrolopyrimidine compounds for the treatment of cancer

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee